作者：冷同爱1，王利2，禚度君1，李春峰2，陈吉刚2，杨琛2

单位：

1.266101 山东省青岛市，中国人民解放军海军第九七一医院崂山医疗区门诊急诊医学科 2.266101 山东省青岛市，中国人民解放军海军第九七一医院崂山医疗区血液科

单位（英文）：

1.Department of Outpatients and Emergency, Laoshan Medical District, No.971 Hospital of Chinese PLA Navy, Qingdao266101, China2.Department of Hematology, Laoshan Medical District, No.971 Hospital of Chinese PLA Navy, Qingdao 266101, China

关键词：

新型冠状病毒肺炎；血浆治疗；治疗结果；安全性；综述

关键词（英文）：

Coronavirus disease 2019; Plasma therapy; Treatment outcome; Safety; Review

中图分类号：

R 512.99

DOI：

10.12114/j.issn.1008-5971.2021.00.102

基金项目：

摘要：

新型冠状病毒肺炎（COVID-19）目前已成为全球公共卫生事件。危重型COVID-19 患者死亡率高， 目前尚无特效治疗手段。恢复期血浆（CP）治疗是通过向患者体内补充康复者血浆内抗体以促进病毒清除，减轻病毒 感染细胞及后续的组织器官损伤。本文基于CP 治疗COVID-19 的最新研究进展，主要综述了CP 治疗对COVID-19 的 疗效及安全性，患者病情严重程度、CP 治疗时机、CP 抗体水平、CP 使用频次对疗效的影响，CP 治疗COVID-19 的 作用机制等方面的内容，以期为临床使用CP 治疗COVID-19 提供参考。

英文摘要：

Coronavirus disease 2019 (COVID-19) has become a global public health event. Critically ill COVID-19 patients are associated with a high mortality rate, and no specific treatment is currently available. Convalescent plasma (CP) treatment is to supplement antibodies in the plasma of the recovered patients to patients to promote virus clearance and reduce virus infected cells and subsequent tissue and organ injuries. Based on the latest research progress in CP treatment in COVID-19, this article mainly reviewed the efficacy and safety of CP in COVID-19, the impact of the severity of the disease, the timing of CP treatment, the level of CP antibody and CP use frequency on the efficacy, and the mechanism of CP in the treatment of COVID-19, so as to provide reference for the clinical use of CP in the treatment of COVID-19.

参考文献：